FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer
Authors:
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Pancreatology
- Vol. 19 (2) , 325-330
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Bending the Cost Curve in Cancer CareNew England Journal of Medicine, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205Journal of Clinical Oncology, 2010
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 StudyJournal of Clinical Oncology, 2010
- Cancer's Next FrontierJAMA, 2010
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2009
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 2008
- Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic CancerJournal of Clinical Oncology, 2007
- Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic CancerJournal of Clinical Oncology, 2006